Investigational agents for polymyalgia rheumatica treatment: assessing the critical needs for future development

References

• Espígol-Frigolé G, Dejaco C, Mackie SL, et al. Polymyalgia rheumatica. Lancet. 2023 Oct 21;402(10411):1459–1472. doi: 10.1016/S0140-6736(23)01310-7
   PubMed Web of Science ®Google Scholar
• Salvarani C, Padoan R, Iorio L, et al. Subclinical giant cell arteritis in polymyalgia rheumatica: concurrent conditions or a common spectrum of inflammatory diseases? Autoimmun Rev. 2023 Aug 23;23(1):103415. doi: 10.1016/j.autrev.2023.103415
   PubMed Web of Science ®Google Scholar
• Bond M, Dejaco C. Polymyalgia rheumatica: crafting the future of a simple (but not easy!) clinical syndrome. Ann Rheum Dis. 2023 Dec 8;83(3):271–273. doi: 10.1136/ard-2023-225192
   Web of Science ®Google Scholar
• Dejaco C, Singh YP, Perel P, et al. Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2015 Oct;74(10):1799–1807. doi: 10.1136/annrheumdis-2015-207492
   PubMed Web of Science ®Google Scholar
• Floris A, Piga M, Chessa E, et al. Long-term glucocorticoid treatment and high relapse rate remain unresolved issues in the real-life management of polymyalgia rheumatica: a systematic literature review and meta-analysis. Clin Rheumatol. 2022 Jan;41(1):19–31. doi: 10.1007/s10067-021-05819-z
   PubMed Web of Science ®Google Scholar
• Pujades-Rodriguez M, Morgan AW, Cubbon RM, et al. Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: a population-based cohort study. PLoS Med. 2020 Dec;17(12):e1003432. doi: 10.1371/journal.pmed.1003432
   PubMed Web of Science ®Google Scholar
• Salvarani C, Cantini F, Olivieri I, et al. Corticosteroid injections in polymyalgia rheumatica: a double-blind, prospective, randomized, placebo controlled study. J Rheumatol. 2000 Jun;27(6):1470–1476.
   PubMed Web of Science ®Google Scholar
• Caporali R, Cimmino MA, Ferraccioli G, et al. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2004 Oct 5;141(7):493–500. doi: 10.7326/0003-4819-141-7-200410050-00005
   PubMed Web of Science ®Google Scholar
• Nazarinia AM, Moghimi J, Toussi J. Efficacy of methotrexate in patients with polymyalgia rheumatica. Koomesh. 2012;14:265–70.
   Google Scholar
• Ferraccioli G, Salaffi F, De Vita S, et al. Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study. J Rheumatol. 1996 Apr;23(4):624–628.
   PubMed Web of Science ®Google Scholar
• van der Veen MJ, Dinant HJ, van Booma-Frankfort C, et al. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? Ann Rheum Dis. 1996 Apr;55(4):218–223. doi: 10.1136/ard.55.4.218
   PubMed Web of Science ®Google Scholar
• Marsman DE, Bolhuis TE, den Broeder N, et al. PolyMyalgia rheumatica treatment with methotrexate in optimal dose in an early disease phase (PMR MODE): study protocol for a multicenter double-blind placebo controlled trial. Trials. 2022 Apr 15;23(1):318. doi: 10.1186/s13063-022-06263-3
   PubMed Web of Science ®Google Scholar
• Adizie T, Christidis D, Dharmapaliah C, et al. Efficacy and tolerability of leflunomide in difficult-to-treat polymyalgia rheumatica and giant cell arteritis: a case series. Int J Clin Pract. 2012 Sep;66(9):906–909. doi: 10.1111/j.1742-1241.2012.02981.x
   PubMed Web of Science ®Google Scholar
• Diamantopoulos AP, Hetland H, Myklebust G. Leflunomide as a corticosteroid-sparing agent in giant cell arteritis and polymyalgia rheumatica: a case series. Biomed Res Int. 2013;2013:120638. doi: 10.1155/2013/120638
   PubMed Web of Science ®Google Scholar
• Doury P, Pattin S, Eulry F, et al. The use of dapsone in the treatment of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum. 1983 May;26(5):689–690. doi: 10.1002/art.1780260521
   PubMedGoogle Scholar
• De Silva M, Hazleman BL. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis. 1986 Feb;45(2):136–138. doi: 10.1136/ard.45.2.136
   PubMed Web of Science ®Google Scholar
• Salvarani C, Macchioni P, Manzini C, et al. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial. Ann Intern Med. 2007 May 1;146(9):631–639. doi: 10.7326/0003-4819-146-9-200705010-00005
   PubMed Web of Science ®Google Scholar
• Kreiner F, Galbo H. Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial. Arthritis Res Ther. 2010;12(5):R176. doi: 10.1186/ar3140
   PubMed Web of Science ®Google Scholar
• Hysa E, Gotelli E, Sammorì S, et al. Immune system activation in polymyalgia rheumatica: which balance between autoinflammation and autoimmunity? A systematic review. Autoimmun Rev. 2022 Feb;21(2):102995. doi: 10.1016/j.autrev.2021.102995
   PubMed Web of Science ®Google Scholar
• Bonelli M, Radner H, Kerschbaumer A, et al. Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial. Ann Rheum Dis. 2022 Jun;81(6):838–844. doi: 10.1136/annrheumdis-2021-221126
   PubMed Web of Science ®Google Scholar
• Devauchelle-Pensec V, Carvajal-Alegria G, Dernis E, et al. Effect of tocilizumab on disease activity in patients with active polymyalgia rheumatica receiving glucocorticoid therapy: a randomized clinical trial. JAMA. 2022 Sep 20;328(11):1053–1062. doi: 10.1001/jama.2022.15459
   PubMed Web of Science ®Google Scholar
• Spiera RF, Unizony S, Warrington KJ, et al. Sarilumab for relapse of polymyalgia rheumatica during glucocorticoid taper. N Engl J Med. 2023 Oct 5;389(14):1263–1272. doi: 10.1056/NEJMoa2303452
   PubMed Web of Science ®Google Scholar
• Rosenzwajg M, Lorenzon R, Cacoub P, et al. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Ann Rheum Dis. 2019 Feb;78(2):209–217. doi: 10.1136/annrheumdis-2018-214229
   PubMed Web of Science ®Google Scholar
• Saraux A, Le Henaff C, Dernis E, et al. Abatacept in early polymyalgia rheumatica (ALORS): a proof-of-concept, randomised, placebo-controlled, parallel-group trial. Lancet Rheumatol. 2023 Dec 01;5(12):e728–e735. doi: 10.1016/S2665-9913(23)00246-1
   PubMedGoogle Scholar
• Reitsema RD, Jiemy WF, Wekema L, et al. Contribution of pathogenic T helper 1 and 17 cells to bursitis and tenosynovitis in polymyalgia rheumatica. Front Immunol. 2022;13:943574. doi: 10.3389/fimmu.2022.943574
   PubMed Web of Science ®Google Scholar
• Dejaco C, Brouwer E, Mason JC, et al. Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities. Nat Rev Rheumatol. 2017 Oct;13(10):578–592. doi: 10.1038/nrrheum.2017.142
   PubMed Web of Science ®Google Scholar
• Xin P, Xu X, Deng C, et al. The role of JAK/STAT signaling pathway and its inhibitors in diseases. Int Immunopharmacol. 2020 Mar;80:106210. doi: 10.1016/j.intimp.2020.106210
   PubMed Web of Science ®Google Scholar
• Ma X, Yang F, Wu J, et al. Efficacy and safety of tofacitinib in patients with polymyalgia rheumatica (EAST PMR): an open-label randomized controlled trial. PLoS Med. 2023 Jun;20(6):e1004249. doi: 10.1371/journal.pmed.1004249
   PubMed Web of Science ®Google Scholar
• Zhang L, Li J, Yin H, et al. Efficacy and safety of tofacitinib in patients with polymyalgia rheumatica: a phase 2 study. Ann Rheum Dis. 2023 May;82(5):722–724. doi: 10.1136/ard-2022-223562
   PubMed Web of Science ®Google Scholar
• Katz D, Mortier M. RF21 | PSAT100 HPA axis modulation by a potent inhibitor indicates 11beta-hydroxysteroid dehydrogenase type 1 (HSD-1) is a significant contributor to cortisol levels. J Endocr Soc. 2022;6(Supplement_1):A135. © The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. doi: 10.1210/jendso/bvac150.275
   Google Scholar
• Hapgood JP, Avenant C, Moliki JM. Glucocorticoid-independent modulation of GR activity: implications for immunotherapy. Pharmacol Ther. 2016 Sep;165:93–113. doi: 10.1016/j.pharmthera.2016.06.002
   PubMed Web of Science ®Google Scholar
• Dejaco C, Kerschbaumer A, Aletaha D, et al. Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica. Ann Rheum Dis. 2024;83(1): 48–57. doi: 10.1136/ard-2022-223429
   PubMed Web of Science ®Google Scholar
• Camellino D, Dejaco C, Buttgereit F, et al. Treat to target: a valid concept for management of polymyalgia rheumatica and giant cell arteritis? Rheum Dis Clin North Am. 2019 Nov;45(4):549–567. doi: 10.1016/j.rdc.2019.07.005
   PubMed Web of Science ®Google Scholar
• Dejaco C, Duftner C, Cimmino MA, et al. Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus. Ann Rheum Dis. 2011 Mar;70(3):447–453. doi: 10.1136/ard.2010.133850
   PubMed Web of Science ®Google Scholar
• Keller KK, Mukhtyar CB, Nielsen AW, et al. Recommendations for early referral of individuals with suspected polymyalgia rheumatica: an initiative from the international giant cell arteritis and polymyalgia rheumatica study group. Ann Rheum Dis. 2023 Dec 1. doi: 10.1136/ard-2023-225134
   Web of Science ®Google Scholar
• Leeb BF, Bird HA. A disease activity score for polymyalgia rheumatica. Ann Rheum Dis. 2004 Oct;63(10):1279–1283. doi: 10.1136/ard.2003.011379
   PubMed Web of Science ®Google Scholar
• Binard A, de Bandt M, Berthelot JM, et al. Performance of the polymyalgia rheumatica activity score for diagnosing disease flares. Arthritis Rheum. 2008 Feb 15;59(2):263–269. doi: 10.1002/art.23338
   PubMedGoogle Scholar